Factors associated with relapse-free survival after neoadjuvant chemotherapy for breast cancer at a safety net medical center

Rachel E Sargent; Elizabeth Vazquez; Irene Kang; Janice Lu; Tejas Manchandia; Pulin Sheth; Alicia Terando; Maria E Nelson; Azadeh Carr; David S Hong; Stephen F Sener

doi:10.1016/j.amjsurg.2021.11.017

Factors associated with relapse-free survival after neoadjuvant chemotherapy for breast cancer at a safety net medical center

Am J Surg. 2022 Mar;223(3):539-542. doi: 10.1016/j.amjsurg.2021.11.017. Epub 2021 Nov 16.

Authors

Affiliations

¹ Los Angeles County + University of Southern California (LAC+USC) Medical Center, Los Angeles, CA, USA; Department of Surgery and Norris Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
² Los Angeles County + University of Southern California (LAC+USC) Medical Center, Los Angeles, CA, USA.
³ Los Angeles County + University of Southern California (LAC+USC) Medical Center, Los Angeles, CA, USA; Department of Medicine and Norris Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
⁴ Los Angeles County + University of Southern California (LAC+USC) Medical Center, Los Angeles, CA, USA; Department of Radiology and Norris Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
⁵ Los Angeles County + University of Southern California (LAC+USC) Medical Center, Los Angeles, CA, USA; Department of Radiation Oncology and Norris Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA.
⁶ Los Angeles County + University of Southern California (LAC+USC) Medical Center, Los Angeles, CA, USA; Department of Surgery and Norris Comprehensive Cancer Center, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA. Electronic address: [email protected].

PMID: 34801227
DOI: 10.1016/j.amjsurg.2021.11.017

Abstract

Background: This study was designed to assess prognostic factors associated with relapse-free survival (RFS) after neoadjuvant chemotherapy (NAC) for breast cancer.

Methods: A single-institution retrospective analysis was performed including clinical, radiographic, and pathologic parameters for all breast cancer patients treated with NAC from 2015 to 2018. All patients had pre-and post-NAC MRI.

Results: For 102 patients, median follow-up was 47.4 months, and the five-year RFS was 74%. The 41 (40%) patients who achieved pathologic complete response (pCR) after NAC had a significantly higher five-year RFS than the 61 not achieving pCR. For 31 patients with triple-negative cancers, the five-year RFS was significantly higher in those achieving pCR vs. no pCR. The 44 (43%) patients who achieved radiographic complete response (rCR) after NAC had similar five-year RFS to the 58 (57%) not achieving rCR.

Conclusion: pCR, node-negativity after NAC, and triple-negative subtype were prognostic factors associated with relapse-free survival after NAC.

Keywords: Breast cancer; Complete response; Hispanic; Neoadjuvant chemotherapy.

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms* / pathology
Chemotherapy, Adjuvant
Disease-Free Survival
Female
Humans
Neoadjuvant Therapy*
Neoplasm Recurrence, Local / drug therapy
Prognosis
Retrospective Studies